|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
Implications for the genetic link between PTC taste status and alcoholism are discussed.
|
16712955 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
We develop a pharmacokinetic model describing how genetic variations in ADH1B, ADH1C, ADH7, ALDH2, and TAS2R38 affect consumption behavior, and alcohol and acetaldehyde levels over time in various tissues of individuals with a particular genotype to predict their susceptibility to alcohol dependence.
|
20714161 |
2010 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
We develop a pharmacokinetic model describing how genetic variations in ADH1B, ADH1C, ADH7, ALDH2, and TAS2R38 affect consumption behavior, and alcohol and acetaldehyde levels over time in various tissues of individuals with a particular genotype to predict their susceptibility to alcohol dependence.
|
20714161 |
2010 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
CTD_human |
We used family-based association methods to test for association between TAS2R38 haplotypes and alcohol dependence as well as a measure of alcohol consumption (Maxdrinks) and age of onset of drinking behaviors in a sample of families densely affected with alcoholism.
|
17250611 |
2007 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
BEFREE |
These results are inconsistent with the view that excessive use of alcohol causes the association between nontasting and alcoholism and are consistent with the view that there is a genetic association between PROP/PTC-tasting and alcoholism.
|
1641428 |
1992 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
BEFREE |
Implications for the genetic link between PTC taste status and alcoholism are discussed.
|
16712955 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.540 |
Biomarker
|
disease |
PSYGENET |
These results are inconsistent with the view that excessive use of alcohol causes the association between nontasting and alcoholism and are consistent with the view that there is a genetic association between PROP/PTC-tasting and alcoholism.
|
1641428 |
1992 |
|
Alcohol Use Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in high-risk families of African-American origin.
|
17250611 |
2007 |
|
Alcohol abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in high-risk families of African-American origin.
|
17250611 |
2007 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we use an 18 Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer.
|
16331264 |
2006 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that there is a high preponderance of ras and ret/PTC oncogenes in the evolution of thyroid cancer.
|
12240753 |
2002 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
|
19495791 |
2009 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, activation of specific subtypes of the ret/PTC tyrosine kinase oncogene appears to be more common in radiation-associated thyroid cancers than in spontaneous thyroid cancers.
|
10787193 |
2000 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms the occurrence of synchronous MTC and PTC and is the first evidence of the co-existence of melanoma and distinct thyroid cancers of different origin.
|
24858900 |
2014 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data suggest that: (1) the incidence of FAP-associated thyroid cancer probably has been underestimated in the past; (2) intensive screening could detect a larger than expected number of thyroid carcinomas; (3) systematic screening is recommended in patients with ocular patches and genetic mutation in exon 15; (4) Hashimoto-like findings do not exclude carcinoma but are a frequent accompanying finding; (5) despite frequent multicentricity and early lymph node involvement, FAP-associated thyroid tumors seem to have an excellent prognosis, in particular those showing ret-PTC activation.
|
9841749 |
1998 |
|
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer.
|
27207655 |
2016 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |